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Controlling biochemical pathways through chemically designed modulators may provide novel 
opportunities to develop therapeutic drugs and chemical tools. The underlying challenge is to design 
new molecular entities able to act as allosteric chemical switches that selectively turn on/off functions 
by modulating the conformational dynamics of their target protein. We examine the origins of the 
stimulation of ATPase and closure kinetics in the molecular chaperone Hsp90 by allosteric modulators 
through atomistic molecular dynamics (MD) simulations and analysis of protein-ligand interactions. In 
particular, we focus on the cross-talk between allosteric ligands and protein conformations and its effect 
on the dynamic properties of the chaperone’s active state. We examine the impact of different allosteric 
modulators on the stability, structural and internal dynamics properties of Hsp90 closed state. A critical 
aspect of this study is the development of a quantitative model that correlates Hsp90 activation to 
the presence of a certain compound, making use of information on the dynamic adaptation of protein 
conformations to the presence of the ligand, which allows to capture conformational states relevant in 
the activation process. We discuss the implications of considering the conformational dialogue between 
allosteric ligands and protein conformations for the design of new functional modulators.
Protein functions are determined by their internal dynamics and are fine-tuned by the interactions with effectors 
of different chemical origins1–3. Most chemical interventions on proteins and enzymes focus on the identification 
of small molecule inhibitors designed to abrogate their activities4, or on the development of agonists that induce 
active-like conformations of the target and subsequent signaling responses by binding to known orthosteric sites5.
In contrast, the rational search for allosteric activators of protein functions is still relatively unexplored6,7. 
However, allosteric activators may provide new opportunities to develop chemical tools to probe the role of 
protein activity in cellular phenotypes: indeed new information can be gained by turning on a signaling pathway 
starting from a specific node of the underlying protein network7,8. Allosteric activators can in principle modulate 
receptor function while still allowing the possibility of orthosteric agonist or antagonist binding. In this context, 
allosteric ligands can act as affinity modulators by changing the affinity of the orthosteric ligand for the receptor, 
as well as induce conformational changes that in turn modulate the efficacy of the orthosteric ligand in determin-
ing cellular responses.
Moreover, activators can help identify and characterize allosteric sites and mechanisms for the discovery of 
novel drug candidates: indeed, since allostery represents one of the most relevant means to regulate protein func-
tion, drug discovery can be extended to target regulatory protein pockets. It has previously been shown that 
sequence variation in allosteric pockets could aid the design of highly specific drugs that would bind only specific 
members of a protein family. Finally, allosteric ligands can potentially modulate the balance between the tar-
get protein conformations that are presented to other interacting proteins, generating the possibility to perturb 
protein-protein interactions (PPIs) through low molecular weight ligands9,10.
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Defining the principles of ligand recognition and allostery is thus important for understanding the molecular 
links between small-molecule binding and observed effects. This would in turn facilitate the generation of novel 
chemical tools and therapeutic agents. Experimental approaches based on X-ray crystallography, tethering, enzy-
matic, biochemical and phenotypical assays have been used to characterize the activation of enzymatic functions 
determined by small molecules6,7,9,10. Despite these exciting advances, experimental techniques are still limited 
in their potential to provide insight at an atomic level into the allosteric activation process itself. To understand 
activation mechanisms at atomistic detail, we can turn to theoretical and computational approaches10,11. The 
latter methods can help address open questions such as the role of variations in protein structures and internal 
dynamics incurred by binding at an allosteric site, and the possibility to quantitatively correlate ligand binding, 
dynamic-changes and observed modulation of a certain activity12.
In this paper, we will address the problem of rationalizing the observed allosteric activation of the 90 kDa Heat 
Shock Protein (Hsp90) molecular chaperone through a set of newly designed ligands12. Members of the Hsp90 
family are hub proteins that control the crossroads of fundamental pathways required for cell development and 
maintenance. The disregulation of Hsp90 functions, often associated with its overexpression, has been shown to 
be at the basis of disease states, such as cancer and neurodegeneration13–19. At the molecular level, the activities 
of Hsp90 are regulated by ATP binding and hydrolysis: the type of bound nucleotide selects the conformational 
sub-states and the transitions among them, which ultimately determine the chaperone’s functional properties20.
From a structural point of view, Hsp90 is a homodimer (see schematic representation in Fig. 1), whereby each 
protomer consists of three distinct structural domains: an N-terminal regulatory Domain (NTD), where the ATP 
binding site is located, a Middle Domain (M-domain) composed of a Large (LMD) and a Small (SMD) subdo-
main, which completes the ATPase site necessary for ATP hydrolysis and binds client proteins, and a C-terminal 
Domain (CTD) that is involved in dimerization21–25. A bipartite client binding site made of residues from both the 
MD and CTD has been identified26,27. This structural organization is common to the various Hsp90 homologues 
from different organisms and cellular compartments21–25,28.
Although the exact mechanisms of coupling between ATP-binding/hydrolysis and the chaperone cycle 
remain partly elusive, combining available crystal structure information and solution state data, Agard and col-
laborators have developed a general model that recapitulates the main traits of nucleotide dependent conforma-
tional changes in Hsp90. In particular, ATP binding in both NTDs from the two protomers stabilizes a closed 
NTD-dimerized activated state, characterized by an excess structural strain that is ultimately responsible for the 
population of an asymmetric conformation28,29. Hydrolysis of one of the two ATPs could then cause a change 
in symmetry (either to a symmetric state or possibly an opposite asymmetric state), providing a mechanism to 
directly couple hydrolysis to rearrangement of the client binding residues identified in the MD:CTD region21–23,28. 
A simple schematics of the mechanism is reported in Fig. 1A.
With the aim of shedding light on the roles of the ATPase in regulating the conformational and cell-functional 
properties of the chaperone, we recently designed a library of small molecules that activate Hsp90 ATPase by 
targeting an allosteric site located 65 Å away from the active site12. The latter, located at the MD:CTD border in a 
region largely overlapping with the client binding site at the interface between the two protomers, was identified 
through the characterization of long-range dynamic coordination patterns based on the analysis of residue-pair 
distance fluctuations30–32. The characterization of the stereochemical and dynamic properties of the allosteric site 
constituted the basis for the optimization of the allosteric ligands, generating compounds able to accelerate the 
chaperone enzymatic activity up to 6 times.
Herein, we examine the origin of the allosteric activation of Hsp90 and set out to lay the basis for the devel-
opment of a predictive model of ligand-induced activation of the protein’s functional dynamics. Through the use 
of comparative analyses of molecular dynamics (MD) simulations of different complexes of the chaperone in the 
presence of allosteric activators, and known inhibitors as controls, we provide molecular-level insights into how 
ligand binding at an allosteric site can affect protein structure, dynamics and, consequently, enzymatic activity. 
We also provide a first, dynamics-based, quantitative model that links the structure of the allosteric ligands to 
experimentally measured activation effects. Finally, we discuss the implications of our work for activator design.
Results and Discussion
To start building a structural and dynamic model of the mechanisms of Hsp90 activation induced by the allosteric 
ligands, we carried out MD simulations of closed ATP-bound Hsp90 in complex with compounds 1, 4, 10, 12, 16, 
18 (Fig. 1B) at the allosteric site (Fig. 1A, top-right), and compared the results with those obtained in the absence 
of compounds (ATP-only). The structures, ATPase and closure rate stimulation effects for the compounds are 
reported in Table 1. We focused on the closed conformation of Hsp90 as a model of the activated state of the 
protein. In this context, our aim is not full sampling of conformational changes or the exhaustive exploration of 
the highly complex free energy landscape of the protein and its modulation by the ligands. Our goal is to shed 
light on the microscopic details of Hsp90 internal dynamics induced by specific ligands that can ultimately be 
linked to the activation of a specific functional state, namely the one related to ATPase activation. This is expected 
to determine dynamic signatures for defined ligand states of the chaperone, providing information on allosteric 
mechanisms.
Structural analysis: Allosteric Activators Stabilize Closed Compact States of the Dimer. We 
first analyzed the frequency distribution of distances between the centers of mass of the N-terminal domains of 
the two protomers in the presence of a certain allosteric ligand, compared to the ATP-only bound states. Only 
backbone atoms were considered in calculation. This parameter informs on the propensity of Hsp90 to populate 
the closed, N-terminal dimerized state in the presence of the allosteric ligand. For the complexes of Hsp90 with 
ATP and allosteric activators, the peaks of the frequency distributions are at similar or slightly shorter distances 
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than the ATP-only simulation, indicating an enhanced propensity to populate closed conformations (Fig. 2A). 
This latter is considered to represent the activated state of the chaperone31,32.
In contrast, control simulations run with known inhibitors (Novobiocin, DHN1, DHN2) show that the peaks 
for the inhibitors are consistently centered at larger NTD-NTD distances (Fig. 2B), indicating a propensity for 
stabilizing a more open, inactive state31,32.
Overall, within the limitations of MD sampling, these results indicate that the allosteric activators tend to 
maintain the protein in an ensemble of structures similar to the ones observed for the ATP-only case, where the 
Figure 1. Hsp90 conformational cycle and structures of allosteric ligands. (A) In the apo state, Hsp90 
populates a number of states with open conformations. Upon ATP and Allosteric Stimulator (AS) binding, the 
chaperone shifts to an asymmetric closed conformation with significant strain, with particular distortions at 
the MD:CTD interface. After the first ATP is hydrolyzed, strain is relieved, and the chaperone moves through 
symmetric states, returning to the open conformation. (B) Molecular structures of the activators and inhibitors 
studied in this work.
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N-terminal organization remains tightly closed. The population of the latter, initiated by ATP (or ATP analogs), is 
a hallmark of Hsp90 activation and represents the catalytically active state of the protein that allows ATPase activ-
ity. In contrast, inhibitors appear to favor less compact conformations by shifting the peak distributions by about 
0.5 nanometers (5 Å) towards more open structures, which may be associated to the selection of non-reactive 
states31,32. As a caveat, it must be stated that these considerations clearly have a mostly qualitative value and more 
efficient sampling methods, based on enhanced sampling techniques, coupled to longer simulation timescales 
might be needed to quantitatively profile the effects of allosteric ligands on Hsp90 free energy landscape.
Allosteric Activators Distort Hsp90 Inducing an Asymmetric State. We next analyzed the 
large-scale distortions determined by the allosteric ligands. To do this, we evaluated the time evolution of 
the angle formed by the principal axis of the N-M domains of each protomer in simulated snapshots with the 
Allosteric Ligand
Avg. LE on ATP-
onlya
Avg. LE on 
Clustersb
Avg. LE on 
Snapshotsc
ATPase (ATP turnover 
rate, min−1)d
1 − 0.24 (0.02) − 0.24 (0.04) − 0.24 (0.04) 1.24
4 − 0.25 (0.03) − 0.25 (0.03) − 0.25 (0.03) 2.27
10 − 0.28 (0.05) − 0.23 (0.04) − 0.23 (0.05) 2.74
12 − 0.28 (0.01) − 0.29 (0.03) − 0.28 (0.03) 2.35
16 − 0.21 (0.04) − 0.23 (0.03) − 0.26 (0.03) 1.17
18 − 0.30 (0.03) − 0.30 (0.03) − 0.30 (0.04) 4.01
LE–ATPase Correlation: −0.90 −0.70 − 0.57
Table 1.  Correlations between Ligand Efficiencies (LE) and Experimentally determined Hsp90 ATPase 
stimulation. aLE of ligand averaged over the best pose value in 10 different protein structures of the ATP-only 
simulation (see text). bLE averaged calculated on the representative structures of the 6 most populated clusters 
from each simulation. cLE averaged calculated on 6 snapshots extracted from the trajectories of each ligand. 
dFrom ref. 12.
Figure 2. Distribution of the distance between the centers of mass of the N-terminal domains in the Hsp90 
complexes with different ligands. Panels A and B show the distributions of the distances of the N-terminal 
domains of the complexes formed with the activating ligands (A) and the inhibiting ligands (B). As a reference, 
all panels include the distributions of the interprotomer distances of the simulations in the presence of ATP only 
(APO).
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principal axis of the same N-M domain in the 2CG9.pdb closed structure, derived from yeast and used a refer-
ence, after alignment of the structures on the CTDs.
In the absence of the allosteric ligands, the two protomers overall show a similar behavior with a limited 
distortion relative to the starting conformation. In contrast, the presence of the activators consistently deter-
mines a clear distinction between the two protomers, with protomer B, which contacts the allosteric ligand more 
extensively, being significantly more distorted than protomer A (Fig. 3). The only exception to this behavior is 
Figure 3. Time evolution of the distortions in the main axes of the two protomers relative to the 2CG9.pdb 
symmetric structure. After alignment of the single protomers belonging to snapshots from the simulations in 
the presence of the allosteric activators on yHsp90 structure (2CG9.pdb) significant differences between the two 
protomers are observed except for the cases of ATP-only and of the complex with compound 16. The black trace 
refers to protomer A; the red trace refers to protomer B.
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represented by the complex formed with compound 16, whose profile is highly similar to that of the ATP-only 
complex. Interestingly, 16 is the derivative showing the least effect on ATPase activity (see Table 1). The rationale 
for this different behavior can be found in the specific structure of the carbohydrate moiety (β -L-Fucose) in 16: 
the cis configuration of the two hydroxy groups at positions C-3 and C-4 and the lack of an OH group at posi-
tion C-6 of the sugar do not favor the formation of stable hydrogen bonding interactions with the side chains of 
E477 and D503 on one of two protomers, which are located on opposite sides of the sugar ring. These residues 
can be ideally targeted by trans OH groups on atoms C-3 and C-4, as well as by on OH substitution on C-6, as in 
the case of compounds 1, 4, 10, and 12 (see Fig. 4). In the case of compound 18, the positively charged tertiary 
amino-group acts as a bridge between the two negatively charged side chains of E477 and D503, through electro-
static interactions. Such network of interactions induces strain in the 3D structure of the protein, which eventu-
ally results in the observed distortion in one of the two protomers, namely the one to which the two interacting 
E477 and D503 side chains belong. The structural details at the basis of the activity of the different ligands are also 
described in our previous paper on allosteric design12.
In this framework, the distortions induced by the activators could favor the population of the asymmetric state 
proposed by Agard and coworkers as a high-energy intermediate for the activation of ATP hydrolysis28,29.
Effects of Allosteric Ligands on Hsp90 Internal dynamics. Next, we turned our attention to the char-
acterization of the effects of allosteric ligands on the internal dynamics of Hsp90, compared to the ATP-only 
case. We first characterized the global rigidity/flexibility patterns in the complexes by calculating the fluctua-
tions of pairwise amino acid distances (this analysis was also named coordination propensity (CP) analysis in 
previous papers30–32). To obtain a compact representation of the data for the different compounds, we calculated 
the difference matrix between all residue pair fluctuations determined for the ATP-only case and all residue 
pair fluctuations determined in the presence of the allosteric ligands. Positive values in the matrix (black color) 
indicate higher flexibility in the ATP-only state, while negative ones (blue color) indicate higher flexibility in 
the allosteric complex. This calculation is then intended to pinpoint the distribution of rigidity/flexibility blocks 
within the protein. As a consequence of ligand binding, amino acids belonging to different domains may change 
their long-distance coordination, coupled to a modulation of the inter-domain rigid dynamics.
In the presence of the activators (Fig. 5 Upper Panel), the patterns of flexibility/rigidity are highly similar to 
the ones of the ATP-only case, as shown by the large white regions, the main differences being that in the allosteric 
complexes the NTDs from one protomer (represented as a light blue domain in the figure) are decoupled from 
the block formed by the Small portion of the Middle Domain (Small-Middle Domain, SMD) and the CTD (rep-
resented as a light red and green domains in the figure) of the other, as indicated by the larger blue-colored blocks. 
Interestingly, the split of the Middle domain into a Large and a Small subdomain is consistent with the domain 
separation observed in the X-ray structure of the mitochondrial Hsp90 homolog TRAP1 and with evolutionary 
studies indicating that Hsp90 and other GHKL family members significantly diverge at this subunit33. These 
results once more suggest a peculiar role for the SMD-CTD unit in regulating functionally oriented aspects of 
Hsp90 conformational dynamics.
By contrast, the high degree of internal coordination between the NTD and MD within each protomer was 
maintained upon compound addition, indicated by the presence of extended white blocks. As observed previ-
ously, intraprotomer coordination of the two domains that make up the active site favors structural preorganiza-
tion for catalysis. In parallel, interprotomer flexibility can be aptly exploited to speed up the search for the closed 
active state, consistent with the observed increases in ATPase.
In contrast, control simulations run in the presence of coumarin-based inhibitors indicate a uniform increase 
in the overall protein flexibility, likely favoring distortions of both protomers and detachment of the two NTDs 
(Fig. 5 Lower Panel). This enhanced flexibility upon addition of a compound is quite unusual as compound bind-
ing normally stabilizes proteins, reducing dynamics. Thus, it may be a hallmark of allosteric inhibitors to work 
by increasing dynamics, favoring transitions away from the ground and catalytically active states. In the case of 
Figure 4. Representative structures of the complexes of Hsp90 with allosteric ligands. The figure shows the 
structures of the complexes of Hsp90 with the compound showing the least activation of ATPase (16), and with 
more potent stimulators, such as 12 and 18. The compounds and Hsp90 residues E477 and D503 are highlighted 
in yellow.
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activators, the modulation of flexibility may work by facilitating Hsp90 to transition through conformations of 
the catalytic cycle.
A Quantitative Structure-Dynamics-Activity Relationship Model for Designed Compounds. 
The design and selection of small molecule inhibitors targeting well-defined enzymatic catalytic sites is now 
routinely accessed through virtual screening. On the other hand, experimental screening approaches can be used 
to select for a certain protein activity. The Wells lab demonstrated the possibility to select for specific kinase and 
caspase activators by combining a tethering approach with crystal structure studies7,34. Work by the Buchner 
lab proved the feasibility of using high-throughput FRET based assays for the discovery of artificial activators of 
Hsp90 35.
However, the computational design of allosteric protein activators still represents a challenging task, in general 
and for Hsp90 in particular. The dynamic nature of the allosteric binding sites, combined with the fact that in 
many cases no direct correlations between the ligand binding affinity values and any effects on chaperone func-
tions or cellular activity can be observed, makes the problem of structure-based activators design particularly 
complex36–38.
To progress along this difficult but fascinating avenue, we set out to explicitly consider the dynamic 
cross-talk between the chaperone and allosteric activators as an integral part of the development of a 
structure-dynamics-activity relationship (SDAR) model. In other words, we made direct use of the dynamic adap-
tation of protein conformations to the presence of the ligand (and vice versa) in deriving a simple model relating 
the physico-chemical properties of the small molecules to their activating effects. On this basis, we chose to 
describe binding in terms of an ensemble of ligand poses in complex with an ensemble of protein structures: in 
this way, protein and ligand conformations that could play a role in the activation process may be captured and 
recapitulated in a simple model.
To achieve this goal, we adopted a Docking over Multiple Receptor Structures (DMRS) approach, originating 
from the ATP-only dynamics: the 10 representatives of the most populated conformational clusters obtained 
from the ATP-only simulation were extracted from the MD trajectory and compounds 1, 4, 10, 12, 16, 18 were 
re-docked into each of the 10 representative structures (see Materials and Methods) (Fig. 6 exemplifies this for 
Figure 5. Difference distance fluctuation matrices for Hsp90 in complexes with different ligands. The 
matrices are calculated as the difference between the magnitude of pairwise distance fluctuations in ATP-only 
simulation and the respective pairwise distance fluctuation in complex with the indicated allosteric ligand. The 
matrices are color coded, from blue (higher flexibility in the complex with an allosteric ligand) to black (higher 
flexibility in the ATP-only state).
www.nature.com/scientificreports/
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compound 18). The Ligand Efficiency (LE) for the best pose of each compound in each of the 10 target Hsp90 
structures was calculated. Ligand efficiency (LE) is a measure of the average binding energy per atom in a certain 
ligand39 and allows comparison of different sized molecules binding the same target. The average LE over the 
best poses obtained from the DMRS calculation (Table 1 – Avg. LE on ATP-only column) strongly correlates for 
each activator with the experimental ATPase rate (Table 1 – ATPase), thus representing a predictive descriptor 
for the evaluation of new modulators. The combination of DMRS and LE computation provides a convenient 
common structural framework to design, dock and evaluate novel compounds, without the need for additional 
computationally expensive MD simulations. As a control, for each activator, we also evaluated the average LE 
from dynamic trajectories of the respective Hsp90 complexes, using the representatives of the most populated 
structural clusters for each dynamics (Table 1 - Avg. LE on Clusters) and on random snapshots extracted from 
the equilibrated parts of the trajectories (Table 1 - Avg. LE on Snapshots). The resulting LE values for each ligand 
were then averaged and correlated to the respective experimentally determined ATPase stimulations (Table 1). 
Interestingly, the correlation coefficients resulted to be higher (− 0.90) using the docked poses in the 10 protein 
structures from the ATP-only simulation, than using the representative structures of the most populated con-
formational clusters of the complex dynamics (− 0.70), or using the representative snapshots extracted from the 
trajectories of the same dynamics (− 0.57). These data indicate that LE evaluated on multiple protein structures 
can aptly capture the salient determinants of observed ATPase activation profiles and allow to extract quantitative 
structure-dynamics-activity relationships for a series of modulators. Control calculations using only one single 
best pose yielded poor correlations in the order of − 0.10. This result underlines the importance of using multiple 
poses of the allosteric ligands in contact with different conformations of the chaperone to facilitate the generation 
of a model that quantitatively correlates the structures and dynamics of ligand/protein complexes to experimen-
tally observed activation of ATPase activity (Fig. 6). To the best of our knowledge, this is one of the first fully 
rational structure-dynamics-activity models for the modulation of chaperone functions induced by allosteric 
small molecule ligands.
We also evaluated the correlations between average LE values and FRET closure rates. A significant correlation 
of − 0.76 could be obtained only when using the poses from DMRS (values of − 0.40 and − 0.30 were obtained 
for the structures obtained from the complex dynamics clusters and snapshots, respectively). We speculate that in 
this latter case, larger conformational changes are relevant to correctly describe the closure process and sampling 
limitations play a key role.
Though based on a limited number of compounds, which is a necessary condition given the high computa-
tional costs of all-atom MD simulations, our data overall support a model whereby the allosteric small molecules 
stabilize specific protein conformations selected from the ensemble around the closed activated state, possibly 
providing a path towards precise control of Hsp90 reactivity.
Indeed, the analysis of the effects of compounds on the structural distortions of Hsp90 highlighted relevant 
patterns for activation. Consistent with the characterization of the time evolution of the angle formed by the 
Figure 6. Multiple binding poses of ligand 18, adapting to multiple conformations of Hsp90. The 
conformational and dynamical variability of the protein in response to the ligand (and vice versa). The inset 
shows a zoom into the allosteric binding site.
www.nature.com/scientificreports/
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principal axes of the N-M domains of each protomer compared to the 2CG9.pdb crystal structure, an evident 
asymmetry in the two protomers emerges in the presence of the allosteric activators, with protomer B (the one 
in contact with the variable functional groups installed on the benzofuran scaffold) consistently showing a larger 
distortion than protomer A (Fig. 7).
In this context, it is possible to hypothesize that different ligand poses modulate the ensemble of protein con-
formations responsible for enzymatic activities. The coupling of dynamic ligand binding to distinct active protein 
conformations defines thus the mechanism for allosteric activation.
The Cross-Talk between Protein and Allosteric Ligand Determines Allosteric Activities. The 
possibility of characterizing the dynamic properties of a protein’s active state can provide a rational basis for 
designing chemical stimulators of its function. The main challenges in this framework involve the advancement of 
drug design to explicitly include the characterization of protein functional dynamics, the development and exper-
imental testing of compounds able to directly modulate the functional substates of the target through selected 
functional groups, and the investigation of the mechanistic consequences of allosteric binding on the functionally 
oriented dynamic properties of the protein. Meeting these challenges can directly contribute to advancing the role 
of chemical design in the investigation of complex biomolecular systems. The long-term perspective is in fact the 
definition of methods for the rational development of new chemical entities able to modulate and not only inhibit 
protein activities linked to cellular functions.
Our work demonstrates that the cross-talk between allosteric ligands and protein conformations can dynami-
cally modulate protein activities. In the conformational selection model of binding and activity, a small molecule 
can preferentially target and stabilize key functional sub-states from an ensemble of conformations available on 
the protein free energy landscape. This concept was for instance at the basis of the design of Gleevec, a potent 
inhibitor of kinase activities, which binds differently to the active conformation of a kinase (Syk) than to the inac-
tive conformation of another (Abl)40.
In this context, we have previously combined conformational selection concepts and studies of 
nucleotide-regulated dynamics for the discovery of an allosteric site in Hsp90 30–32. Next, we used the knowledge 
of the stereoelectronic properties of the allosteric site to select a small molecule lead binder. This was then evolved 
into a small library of derivatives showing the ability to allosterically activate Hsp90 ATPase and closure dynam-
ics. More potent activators were then designed through the rational modification of the functionalities decorating 
the benzofuran scaffold to exploit potential productive interactions with the network of charged amino acids in 
the allosteric pocket, resulting in compounds able to accelerate Hsp90 enzymatic activity and closure kinetics by 
up to 6 times12.
Building on these results, herein we set out to generate a comprehensive structural, dynamic and activity 
model to link the presence of specific allosteric ligands to the experimentally observed activation of Hsp90 func-
tional stimulation. Binding of allosteric activators determines the stabilization of the closed N-terminal dimerized 
Figure 7. Asymmetric Distortion Induced by Compound 18. Global alignment of the protomers of Hsp90 
in the ATP-only state (light blue) and in complex with ligand 18 (red) shows significant differences in the 
distortions of protomer A and B.
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state of the chaperone necessary for catalysis and function, as shown by the consistent increase in the number 
of NTD-NTD contacts during MD simulations. Control simulations in the presence of known inhibitors show a 
clear disruption of the NTD-NTD contacts.
In parallel, analysis of Hsp90 internal dynamics using the distance fluctuation Coordination Propensity (CP) 
parameter highlights lower interprotomer coordination in the presence of the allosteric activators. In this case, an 
asymmetric behavior emerges as well: in protomer A, in fact, high coordination entails all the NTD and M-large 
regions. The subdomains of protomer B, on the other hand, show patterns similar to those observed for the 
ATP-only cases.
Although never previously observed with a eukaryotic cytosolic Hsp90, the proposed formation of an asym-
metric, activated state is consistent with recent results by the Agard Lab based on the crystal structures of the 
mitochondrial Hsp90 Trap1 and studies on the bacterial Hsp90 HtpG. These results indicate that after ATP bind-
ing at the NTD, a high-energy asymmetric state is populated which favors sequential ATP hydrolysis by the two 
protomers28,29. The ligand-induced increased flexibility coupled to the differential structural and dynamic profiles 
between the two protomers observed here can favor the global rearrangements that lead to and stabilize the for-
mation of the high-energy asymmetric catalytically competent state, eventually resulting in ATPase stimulation.
Conclusions
Overall, our findings establish that the interactions between the allosteric ligands and the closed active conforma-
tions of Hsp90 can direct functional dynamics towards the preferential population of compact asymmetric states, 
in which conformers of the chaperone that are optimally poised for ATPase are selected, collectively determin-
ing the observed biological activity. This model is consistent with the description of allosteric activation events 
recently proposed by Nussinov and coworkers41, whereby different states of a protein can be separated by a certain 
surmountable free energy barrier, and binding of the allosteric effectors shifts the population eliciting allosteric 
effects. In this context, the small molecule effector acts as a conformational catalyst that favors the protein’s tran-
sition to the active state, lowering the barrier for the population shift. Moreover, our work also highlights the 
functional importance of transient asymmetric states in otherwise symmetric protein assemblies.
While still hampered by the inherent limitations of MD sampling for such a large and complex system as 
Hsp90, our work begins to define how allosteric ligands can elicit modulated responses in their target proteins, 
while at the same time shedding light on the underlying mechanisms of protein dynamics and setting the stage 
for the use of computational approaches to rationally design chaperone activators. These aspects can have impor-
tant implications in the development of allosteric modulators with graded activities for a number of relevant 
targets, including for instance nuclear receptors, kinases, caspases and GPCRs. In all these contexts, the availa-
bility of chemical tools that allow the control and modulation of the functional dynamics of proteins (and their 
networks) can have fundamental impact on physiology studies and the development of novel mechanism-based 
therapeutics.
Materials and Methods
Molecular Dynamics Simulations. The starting structures of MD simulations of Hsp90 in complex with 
the allosteric ligand compounds were obtained from docking calculations, using the most representative protein 
conformation of previous MD simulations of Hsp90 in the ATP bound state30. The receptor preparation was 
performed using the “Protein Preparation Wizard” suite of the MAESTRO program (see www.Schrodinger.com). 
Bond orders and atomic charges were assigned, and hydrogen atoms were added. The assignments of protona-
tion states for basic and acidic residues were based on the optimization of hydrogen bonding patterns. The final 
minimization of the protein was performed with the default parameters of the Preparation Wizard. The allosteric 
binding site previously defined30 was mapped onto a grid with dimensions of 36 Å (enclosing box) and 14 Å 
(ligand diameter midpoint box), centered on residues 474–487, 502–503, 591–599, 602–603, and 652–657 from 
chain A and residues 502–504, 591–595, and 656–662 from chain B (Hsp90 residues numbering as in the PDB 
entry 2CG921. Docking calculations were performed using the program Glide (version 5.8 Schrödinger, LLC, New 
York, NY, 2012)42,43, keeping the receptor rigid and allowing flexibility for the ligand. Docking calculations were 
performed in Standard Precision mode (SP) with the OPLS-AA (2001) force field44, non-planar conformations 
of amide bonds were penalized, Van der Waals radii were scaled by 0.80, and the partial charge cutoff was fixed to 
0.15. No further modifications were applied to the default settings.
The best poses of the docking runs, according to the Emodel empirical scoring function implemented in 
MAESTRO (www.Schrodinger.com), of the ATP-bound state of Hsp90 together with allosteric compounds 
(Novobiocin derived inhibitors and Benzofuran based activators) were then used as a starting point for all-atom 
MD simulations in explicit water.
The simulation and the analysis of the trajectory were performed using the GROMACS45 software package 
using the GROMOS96 53A6 force field46. In order to remove any bad contacts, the complex was initially mini-
mized in vacuo by multiple minimizations (200 steps steepest descent plus 200 steps conjugate gradient). Then 
the system was solvated in a tetrahedral box large enough to contain the protein and 1.0 nm of solvent around it 
on each side. The SPC water model was used for solvation47, and Na+ counterions were added to ensure electro-
neutrality. In order to allow the solvent molecules to relax around the solute, the system was minimized with posi-
tion restraints on the protein and ligand and just minimizing the positions of water and ions (500 steps steepest 
descent plus 200 steps conjugate gradient). After this minimization step, the whole system was equilibrated by a 
100 ps of MD run in the NVT ensemble to allow the temperature reaching a plateau at 300 K48. The first equilibra-
tion run was followed by a second 100 ps run in the NPT ensemble to adjust the pressure and the density of the 
system, by weak coupling to a bath of constant pressure (P0 = 1 bar, coupling time τ P = 0.5 ps)48. The first 20 ns of 
the trajectory were not used in the subsequent analysis in order to minimize convergence artifacts.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:23830 | DOI: 10.1038/srep23830
Equilibration of the trajectory was checked by monitoring the equilibration of quantities, such as the 
root-mean-square deviation (rmsd) with respect to the initial structure, the internal protein energy, and fluctua-
tions were calculated on different time intervals. The electrostatic term was described by using the particle mesh 
Ewald algorithm49, the LINCS algorithm50 was used to constrain all bond lengths and the SETTLE algorithm51 
was used for water molecules. A dielectric permittivity, ε = 1, and a time step of 2 fs were used. All atoms were 
given an initial velocity obtained from a Maxwellian distribution at the desired initial temperature of 300 K. In all 
simulations, the temperature was maintained close to the intended values by weak coupling to an external tem-
perature bath with a coupling constant of 0.1 ps. The proteins and the rest of the system were coupled separately 
to the temperature bath48. Each Hsp90/allosteric molecule complex was run for 100 ns. Three replicas were run 
for each complex.
All analyses were carried out with the tools available in the Gromacs suite and with in house developed soft-
ware. For the contact analysis reported in Fig. 2, a contact is considered to be present if the distance between any 
pairs of atoms from two residues belonging to different protomers was lower than 6 Å.
Protein internal dynamics. To analyze the impact of each compound on protein internal dynamics, we 
made use of the previously introduced distance fluctuation analysis. For each MD trajectory in complex with an 
allosteric ligand (activator or inhibitor) we computed on the time interval 25–100 ns (the first 25 ns trajectory are 
removed in order to avoid equilibration artifacts), the matrix of distance fluctuations, corresponding to the CP 
parameter31:
= 〈 − 〈 〉 〉CP d d( ) (1)ij ij ij
2
where dij is the (time-dependent) distance of the Cα atoms of amino acids i and j and the brackets indicate the 
time-average over the trajectory. Notice that CP is invariant under translations and rotations of the molecules 
and, unlike the covariance matrix, does not depend on the choice of a particular protein reference structure. The 
CP matrix, and various quantities derived from it, can be used to characterize the salient elasticity and plasticity 
properties of a protein undergoing structural fluctuations. The presence of specific coordination patterns and 
quasi-rigid domains in the protein of interest should reflect in specific properties of CP. In fact, pairs of amino 
acids belonging to the same quasi-rigid domain should be associated with much smaller distance fluctuations 
than amino acid pairs in different domains.
The CP values obtained from three different 100 ns MD trajectories for each allosteric ligand were averaged. 
The same was done with the matrix corresponding to the ATP-only case. We first characterized the global effects 
of ligands on chaperone dynamics by calculating the fluctuations of pairwise amino acid distances on all possible 
residue pairs: the data obtained for the simulations of Hsp90 in complex with both ATP plus allosteric ligands 
were subtracted with the ones obtained for the chaperone in complex with ATP only, and reported in the matrices 
analyzed in the text. This allws to identify residues that change their coordination upon ligand binding.
Axes and angles. In order to investigate the internal rearrangement of the protein induced by the com-
pounds, in particular the asymmetry of the protein and the distortion within each monomer, we defined two 
different axes of inertia of every protomer and then we determined the two angles between them. To do this, all 
the trajectories were sampled every 500 ps starting at 50 ns, obtaining 100 structures per simulation. Using the 
program Chimera (v 1.9)52 each monomer of all protein conformations was superimposed on the CTD of the cor-
responding monomer in the crystal structure of Hsp90 (PDB code: 2CG9). Two axes per monomer were defined: 
the first along the entire protomer and the second comprising only the NTD and Middle domains. To determine 
the axes, in all cases we used only residues forming the conserved secondary elements along the simulation time.
We then measured all the angles formed by NM axis of this protomer and all the other protomers, considering 
the average on the three replicas. Finally we calculated the difference (NM monomer B - NM monomer A) of each 
structure, reporting the asymmetrical rearrangement of the protein along the simulation time due to the presence 
of different compounds. In order to highlight the internal deformation of each protomer, we also measured the 
angle between the entire monomer and its NM axis considering, as stated above, the average values of the replicas 
and then the differences (chain B - chain A).
Structural Cluster Analysis. Structural cluster analysis of the trajectories was carried out by the method 
described by Daura and coworkers53. Briefly: count the number of neighbors using a cut-off of 0.2 nm for RMSD 
between the optimal backbone superimposition of the sampled structures, then take the structure with the largest 
number of neighbors with all its neighbors as cluster and eliminate it from the pool of clusters. This procedure 
is repeated for the remaining structures in the pool. The RMSD was calculated on the backbone atoms of the 
C-terminal domain. We kept the first ten structures for the docking calculations, representing more than 95% of 
the structure variability.
Quantitative Structure-Dynamics-Activity Relationships (QSDAR). The first ten most populated 
structures resulting from the cluster analysis of the MD simulations of Hsp90 in the ATP bound state described 
in30 without any ligand at CTD were used for docking calculations in the DMRS approach. To extract control 
data from the complex dynamics, the representative structures of the 6 most populated clusters resulting from 
the combined analysis of the MD trajectories produced for the closed ATP-bound Hsp90 in complex with com-
pounds 1, 4, 10, 12, 16, 18 (Table 1 - clusters) or the structures of 6 snapshots (for each ligand complex) extracted 
from the equilibrated part of the same MD trajectories (Table 1 – snapshots) were used. In DMRS, re-docking cal-
culations were carried out using the grid described in the Molecular Dynamics Simulations paragraph. Docking 
calculations were carried out with the program Glide43 in Extra Precision mode (XP) with standard OPLS-AA 
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(2001) force field and, in order to refine the conformational search, 20000 poses per ligand for the initial phase of 
docking were saved with a scoring window for keeping initial poses within 200 kcal/mol, keeping up to the best 
800 poses per ligand for successive energy minimization.
In the second and third case, LE was simply calculated as a Glide score given calculated with MAESTRO on 
the respective structures.
At the end of calculation the experimental data of the ATP-ase activity and FRET measurements were cor-
related by Pearson coefficient with the Average Ligand Efficiency calculated based on the Glide-score, given by 
Glide in all ten conformations of the complexes (results are shown in Table 1).
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